全部照片(1)

重要文件

來源證明/COA

檢視所有文件

1469005

USP

炔诺酮

Name: 炔诺酮
Brand: USP

United States Pharmacopeia (USP) Reference Standard

同義詞:

17α-乙炔基-19-去甲睾酮, 17-羟基-19-去甲-17α-孕甾-4-烯-20-炔基-3-酮, 17α-乙炔基-17β-羟基-19-去甲-4-雄甾烯-3-酮, 19-去甲-17α-乙炔基-4-雄甾烯-17β-醇-3-酮, 去甲基脱氢羟孕酮

登入查看組織和合約定價

全部照片(1)

About This Item

經驗公式（希爾表示法）:

C₂₀H₂₆O₂

CAS號碼:

68-22-4

分子量：:

298.42

Beilstein:

1915671

EC號碼:

200-681-6

MDL號碼:

MFCD00067596

分類程式碼代碼:

41116107

PubChem物質ID:

329750580

NACRES:

NA.24

暫時無法取得訂價和供貨情況

推薦產品

Slide 1 of 10

1 of 10

USP

1242000

红霉素

BP266

炔诺酮

N1200000

炔诺酮

USP

1098231

Cefuroxime Axetil Delta-3-Isomers

USP

1370906

利奈孕酮

USP

1250008

雌二醇

USP

1173235

去氧孕烯

BP501

左炔诺孕酮

Supelco

PHR1850

左炔诺孕酮

Supelco

PHR1714

炔诺酮（去甲脱氢羟孕酮）

等級

pharmaceutical primary standard

API 家族

norethindrone

製造商／商標名

USP

mp

205-206 °C (lit.)

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

InChI 密鑰

VIKNJXKGJWUCNN-XGXHKTLJSA-N

基因資訊

human ... PGR(5241)

尋找類似的產品？前往產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Norethindrone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Norethindrone Tablets
Norethindrone Acetate Tablets
Norethindrone and Mestranol Tablets
Norethindrone and Ethinyl Estradiol Tablets
Fluocinolone Acetonide Cream
Fluoxymesterone Tablets

生化／生理作用

炔诺酮是用于抑制细胞溶质磺基转移酶类 (SULT) 的口服避孕药。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

其他說明

Sales restrictions may apply.

訊號詞

Danger

危險聲明

H351,H360FD,H362,H410

防範說明

P201 - P260 - P263 - P280 - P308 + P313

危險分類

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助，請聯絡客戶支援

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Central venous sinus thrombosis in a young woman taking norethindrone acetate for dysfunctional uterine bleeding: case report and review of literature.

Rajesh Rajput et al.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 30(8), 680-683 (2008-09-13)

The association between the progestin-only pill used for treatment of menstrual disorders and central venous sinus thrombosis (CVST) has rarely been reported in the literature. This report describes a case of central venous sinus thrombosis following intake of norethindrone acetate

Norethindrone--a review of therapeutic applications.

H F Taitel et al.

International journal of fertility and menopausal studies, 40(4), 207-223 (1995-07-01)

Norethindrone is utilized for numerous noncontraceptive therapies, especially during the menopause. Through an analysis of the literature we have described the pharmacological profile of norethindrone and the potential therapeutic implications of low-dose therapies, with an emphasis on endometrial pathology, climacteric

Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women.

L R Wiseman et al.

Drugs & aging, 4(3), 238-256 (1994-03-01)

The combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and norethisterone into the systemic circulation at a constant rate for up to 4 days when affixed to the skin. Transdermal administration avoids hepatic first-pass metabolism, allowing therapeutic

HT update: spotlight on estradiol/norethindrone acetate combination therapy.

Colleen L Casey et al.

Clinical interventions in aging, 3(1), 9-16 (2008-05-21)

Abstract: The goal ofpostmenopausal hormone therapy is to alleviate the symptoms that are associated with the loss of estrogen. Many formulations of estrogen and progestin are available, depending on the needs and circumstances of each individual woman. For postmenopausal women

The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.

Kristof Chwalisz et al.

Reproductive sciences (Thousand Oaks, Calif.), 19(6), 563-571 (2012-03-30)

Gonadotropin-releasing hormone agonists (GnRHa) are an effective treatment of endometriosis-associated pelvic pain. The use of hormonal add-back therapy can alleviate the hypoestrogenic symptoms associated with GnRHa therapy, while preserving therapeutic efficacy. Norethindrone acetate (NETA) is a unique progestin that has

查看所有相關論文

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務